Optic Neuropathy-Pipeline Review, H1 2016

Optic Neuropathy-Pipeline Review, H1 2016


  • Products Id :- GMDHC7757IDB
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Optic Neuropathy-Pipeline Review, H1 2016', provides an overview of the Optic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy

The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects

The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Optic Neuropathy

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Optic Neuropathy Overview 7

Therapeutics Development 8

Pipeline Products for Optic Neuropathy-Overview 8

Pipeline Products for Optic Neuropathy-Comparative Analysis 9

Optic Neuropathy-Therapeutics under Development by Companies 10

Optic Neuropathy-Therapeutics under Investigation by Universities/Institutes 11

Optic Neuropathy-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Optic Neuropathy-Products under Development by Companies 15

Optic Neuropathy-Products under Investigation by Universities/Institutes 16

Optic Neuropathy-Companies Involved in Therapeutics Development 17

BioAxone BioSciences, Inc. 17

Inotek Pharmaceuticals Corporation 18

Neurotech Pharmaceuticals, Inc. 19

PharmatrophiX, Inc. 20

Quark Pharmaceuticals, Inc. 21

Regenera Pharma Ltd. 22

Optic Neuropathy-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

BA-240-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

LM22A-4-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

NT-501-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

QPI-1007-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

RPh-201-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecules for CNS Disorders and Ophthalmology-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules for Neurological and Ophthalmological Diseases-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Synthetic Peptide to Inhibit Connexin for Optic Neuropathy-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

trabodenoson-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Optic Neuropathy-Recent Pipeline Updates 48

Optic Neuropathy-Dormant Projects 51

Optic Neuropathy-Product Development Milestones 52

Featured News & Press Releases 52

Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION 52

Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy 52

Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Figures

Number of Products under Development for Optic Neuropathy, H1 2016 8

Number of Products under Development for Optic Neuropathy-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Products, H1 2016 14

Assessment by Monotherapy Products, H1 2016 23

Number of Products by Targets, H1 2016 24

Number of Products by Stage and Targets, H1 2016 24

Number of Products by Mechanism of Actions, H1 2016 26

Number of Products by Stage and Mechanism of Actions, H1 2016 26

Number of Products by Routes of Administration, H1 2016 28

Number of Products by Stage and Routes of Administration, H1 2016 28

Number of Products by Molecule Types, H1 2016 30

Number of Products by Stage and Molecule Types, H1 2016 30

List of Tables

Number of Products under Development for Optic Neuropathy, H1 2016 8

Number of Products under Development for Optic Neuropathy-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Development, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Investigation by Universities/Institutes, H1 2016 16

Optic Neuropathy-Pipeline by BioAxone BioSciences, Inc., H1 2016 17

Optic Neuropathy-Pipeline by Inotek Pharmaceuticals Corporation, H1 2016 18

Optic Neuropathy-Pipeline by Neurotech Pharmaceuticals, Inc., H1 2016 19

Optic Neuropathy-Pipeline by PharmatrophiX, Inc., H1 2016 20

Optic Neuropathy-Pipeline by Quark Pharmaceuticals, Inc., H1 2016 21

Optic Neuropathy-Pipeline by Regenera Pharma Ltd., H1 2016 22

Assessment by Monotherapy Products, H1 2016 23

Number of Products by Stage and Target, H1 2016 25

Number of Products by Stage and Mechanism of Action, H1 2016 27

Number of Products by Stage and Route of Administration, H1 2016 29

Number of Products by Stage and Molecule Type, H1 2016 31

Optic Neuropathy Therapeutics-Recent Pipeline Updates, H1 2016 48

Optic Neuropathy-Dormant Projects, H1 2016 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

BioAxone BioSciences, Inc.

Inotek Pharmaceuticals Corporation

Neurotech Pharmaceuticals, Inc.

PharmatrophiX, Inc.

Quark Pharmaceuticals, Inc.

Regenera Pharma Ltd.

Optic Neuropathy Therapeutic Products under Development, Key Players in Optic Neuropathy Therapeutics, Optic Neuropathy Pipeline Overview, Optic Neuropathy Pipeline, Optic Neuropathy Pipeline Assessment

select a license

Single User License
USD 2000 INR 128160
Site License
USD 4000 INR 256320
Corporate User License
USD 6000 INR 384480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com